Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769305 | 0.83 | BACE1 (0.64) | ALDH1A1HPGDKDM4EGLAPOLB | |
| SCHEMBL3431601 | 0.83 | BACE1 (0.64) | ALDH1A1HPGDKDM4EGLAPOLB | |
| SCHEMBL29746469 | 0.78 | CYP1A2 (0.46) | BACE1NR4A2CYP3A4TSHRTDP1 | |
| SCHEMBL239860 | 0.78 | CYP1A2 (0.46) | BACE1NR4A2CYP3A4TSHRTDP1 | |
| SCHEMBL13077349 | 0.77 | MAOA (0.41) | ALDH1A1HPGDKDM4EGLAPOLB | |
| SCHEMBL707745 | 0.75 | BACE1 (0.66) | KMT2ABACE1CYP3A4TSHRTDP1 | |
| SCHEMBL1615737 | 0.75 | ACHE (0.45) | ALDH1A1HPGDKDM4EKMT2ARAB9A | |
| SCHEMBL29987443 | 0.75 | MAOA (0.40) | RAB9ANPC1GAABACE1CYP3A4 | |
| SCHEMBL7219172 | 0.75 | CYP1A2 (0.44) | ALDH1A1HPGDKDM4EPOLBBACE1 | |
| SCHEMBL3338347 | 0.75 | MAOA (0.40) | RAB9ANPC1GAABACE1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247316-B1 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2424838-A1 | PESTICIDAL ARYLPYRROLIDINES | Bayer CropScience AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| CN-101516852-B | Quinoline derivatives with 5-ht-binding properties | HOFFMANN LA ROCHE | 2011-11-16 | — | — | CN | disclosed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110027178-A1 | IMAGING THE CENTRAL NERVOUS SYSTEM | GE HEALTHCARE LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | ABBOTT LABORATORIES | 2006-12-07 | — | — | US | disclosed |
| WO-2006110516-A1 | ACYLHYDRAZIDE P2X7 ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1832925-A | New p2x7 receptor avtagonists and their use | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | disclosed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | DDT, AADAC, AHR | ALDH1A1 103/4885HPGD 1779/4885KDM4E 237/4885 |
| US-20110027178-A1 | IMAGING THE CENTRAL NERVOUS SYSTEM | P2RX3, P2RX7, P2RX2 | ALDH1A1 2602/4885HPGD 1970/4885KDM4E 4040/4885 |
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | P2RX7, P2RX3, P2RX1 | ALDH1A1 1492/4885HPGD 751/4885KDM4E 1782/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | ALDH1A1 91/4885HPGD 2302/4885KDM4E 3547/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | ALDH1A1 852/4885HPGD 766/4885KDM4E 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.